Methods and reagents for reverse-transcription polymerase chain reaction
The present invention provides a method of amplifying an RNA molecule in a biological sample by reverse transcription PCR (RT-PCR), wherein the RT-PCR is carried out in a solution comprising a polar aprotic solvent; a serum albumin, and a polyol.
1. A method of amplifying an RNA molecule in a biological sample by a reverse transcription PCR (RT-PCR) reaction, wherein the RT-PCR reaction is carried out in a solution comprising:
a. a polar aprotic solvent;
b. a serum albumin; and
c. a polyol;
the method comprising:
i) contacting a solid support having a lysis agent embedded thereon with the biological sample containing the RNA molecule, wherein the RNA molecule becomes immobilized on the solid support;
ii) transferring the solid support or a portion thereof with the lysis agent to a reaction vessel; and
iii) performing the RT-PCR reaction in the reaction vessel in the solution in the presence of the solid support with the lysis agent,
wherein the biological sample has not undergone an RNA purification step prior to the RT-PCR reaction.
2. The method according to claim 1 , wherein the polar aprotic solvent is DMSO (dimethyl sulfoxide).
3. The method according to claim 1 , wherein the serum albumin is bovine serum albumin (BSA).
4. The method according to claim 1 , wherein the polyol is glycerol.
5. The method according to claim 1 , wherein the solution further comprises a reducing agent.
6. The method according to claim 5 , wherein the reducing agent is dithiothreitol (DTT) or Tris(2-carboxyethyl) phosphine hydrochloride (TCEP).
7. The method according to claim 1 , wherein the solution further comprises a non-ionic surfactant.
8. The method according to claim 1 , wherein the solution further comprises a non-ionic surfactant and a betaine.
9. The method according to claim 7 , wherein the non-ionic surfactant is Triton X-100, Brij 56 or Brij 58.
10. The method according to claim 8 , wherein the betaine is N,N,N-trimethylglycine.
11. The method according to claim 1 , wherein the solution comprises:
a. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), and BSA at a concentration in the range 0.05 to 1.2% (w/v); or
b. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), BSA at a concentration in the range 0.05 to 1.2% (w/v), and DTT or TCEP at a concentration in the range 0.5 to 20 mM; or
c. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), BSA at a concentration in the range 0.05 to 1.2% (w/v), Triton X-100 at concentration in the range 0.05 to 1% (v/v); or
d. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), BSA at a concentration in the range 0.05 to 1.2% (w/v), Triton X-100 at concentration in the range 0.05 to 1% (v/v), and N,N,N-trimethylglycine at a concentration in the range 0.05 to 2M.
12. The method according to claim 1 , wherein the solution further comprises:
a. a reverse transcriptase;
b. a DNA polymerase;
c. a deoxyribonucleotide triphosphate (dNTP); and
d. at least one primer.
13. The method according to claim 1 , wherein the biological sample has not undergone treatment with a DNase prior to the RT-PCR reaction.
14. A method according to claim 1 , further comprising subjecting the biological sample to a lysis step and a detergent neutralization step prior to contacting the biological sample with the solution.
15. The method according to claim 14 , wherein the lysis step is performed by contacting the biological sample with a detergent, and the detergent neutralization step is performed by contacting the sample with a cyclodextrin.
16. The method of according to claim 1 , wherein the biological sample comprises a cellular sample selected from the group consisting of blood, serum, semen, cerebral spinal fluid, synovial fluid, lymphatic fluid, saliva, buccal, cervical cell, vaginal cell, urine, faeces, hair, skin, muscle, and cells grown in culture.
17. The method according to claim 1 , wherein the biological sample is derived from a virus, a eukaryotic organism or a prokaryotic organism.
18. The method according to claim 16 , wherein the biological sample is a blood sample, optionally where the blood has been treated with an anti-coagulant.
19. The method according to claim 1 , wherein the solid support:
(a) is fibrous, optionally comprising a cellulose fibre material or a glass fibre or glass microfiber material; or
(b) comprises a porous polymer or porous membrane material such as polyester, polyether sulfone (PES), polyamide (Nylon), polypropylene, polytetrafluoroethylene (PTFE), polycarbonate, cellulose nitrate, cellulose acetate or alignate; or
(c) comprises aluminium oxide.
20. A method of amplifying an RNA molecule in a biological sample by reverse transcription PCR (RT-PCR) reaction, wherein the RT-PCR reaction is carried out in a solution comprising:
a. a polar aprotic solvent;
b. a serum albumin; and
c. a polyol;
the method comprising:
i) contacting a solid support having (i) a weak base; (ii) a chelating agent; (iii) an anionic surfactant and (iv) a chaotropic agent such as guanidium thiocyanate impregnated thereon with the biological sample containing the RNA, wherein the RNA becomes immobilized on the solid support;
ii) transferring the solid support or a portion thereof with the (i) a weak base; (ii) a chelating agent; (iii) an anionic surfactant and (iv) a chaotropic agent to a reaction vessel; and
iii) performing the RT-PCR reaction in the reaction vessel in the solution in the presence of the solid support with the (i) a weak base; (ii) a chelating agent; (iii) an anionic surfactant and (iv) a chaotropic agent wherein the biological sample has not undergone an RNA purification step prior to the RT-PCR reaction.
21. The method according to claim 20 , wherein the polar aprotic solvent is DMSO (dimethyl sulfoxide).
22. The method according to claim 20 , wherein the serum albumin is bovine serum albumin (BSA).
23. The method according to claim 20 , wherein the polyol is glycerol.
24. The method according to claim 20 , wherein the solution further comprises a reducing agent.
25. The method according to claim 24 , wherein the reducing agent is dithiothreitol (DTT) or Tris(2-carboxyethyl) phosphine hydrochloride (TCEP).
26. The method according to claim 20 , wherein the solution further comprises a non-ionic surfactant.
27. The method according to claim 20 , wherein the solution further comprises a non-ionic surfactant and a betaine.
28. The method according to claim 26 , wherein the non-ionic surfactant is Triton X-100, Brij 56 or Brij 58.
29. The method according to claim 27 , wherein the betaine is N,N,N-trimethylglycine.
30. The method according to claim 20 , wherein the solution comprises:
a. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), and BSA at a concentration in the range 0.05 to 1.2% (w/v); or
b. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), BSA at a concentration in the range 0.05 to 1.2% (w/v), and DTT or TCEP at a concentration in the range 0.5 to 20 mM; or
c. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), BSA at a concentration in the range 0.05 to 1.2% (w/v), Triton X-100 at concentration in the range 0.05 to 1% (v/v); or
d. DMSO at a concentration in the range 0.05 to 10% (v/v), glycerol at a concentration in the range 0.05 to 15% (v/v), BSA at a concentration in the range 0.05 to 1.2% (w/v), Triton X-100 at concentration in the range 0.05 to 1% (v/v), and N,N,N-trimethylglycine at a concentration in the range 0.05 to 2M.
31. The method according to claim 20 , wherein the solution further comprises:
a. a reverse transcriptase;
b. a DNA polymerase;
c. a deoxyribonucleotide triphosphate (dNTP); and
d. at least one primer.
32. The method according to claim 20 , wherein the biological sample has not undergone treatment with a DNase prior to the RT-PCR reaction.
33. A method according to claim 20 , further comprising subjecting the biological sample to a lysis step and a detergent neutralization step prior to contacting the biological sample with the solution.
34. The method according to claim 33 , wherein the lysis step is performed by contacting the biological sample with a detergent, and the detergent neutralization step is performed by contacting the sample with a cyclodextrin.
35. The method of according to claim 20 , wherein the biological sample comprises a cellular sample selected from the group consisting of blood, serum, semen, cerebral spinal fluid, synovial fluid, lymphatic fluid, saliva, buccal, cervical cell, vaginal cell, urine, faeces, hair, skin, muscle, and cells grown in culture.
36. The method according to claim 20 , wherein the biological sample is derived from a virus, a eukaryotic organism or a prokaryotic organism.
37. The method according to claim 35 , wherein the biological sample is a blood sample, optionally where the blood has been treated with an anti-coagulant.
38. The method according to claim 20 , wherein the solid support:
(a) is a cellulose fibre material or a glass fibre or glass microfiber material; or
(b) comprises a porous polymer or porous membrane material such as polyester, polyether sulfone (PES), polyamide (Nylon), polypropylene, polytetrafluoroethylene (PTFE), polycarbonate, cellulose nitrate, cellulose acetate or alignate; or
(c) comprises aluminium oxide.